CA2303591A1 - Method and compositions for preventing or reducing hiv infection - Google Patents

Method and compositions for preventing or reducing hiv infection Download PDF

Info

Publication number
CA2303591A1
CA2303591A1 CA 2303591 CA2303591A CA2303591A1 CA 2303591 A1 CA2303591 A1 CA 2303591A1 CA 2303591 CA2303591 CA 2303591 CA 2303591 A CA2303591 A CA 2303591A CA 2303591 A1 CA2303591 A1 CA 2303591A1
Authority
CA
Canada
Prior art keywords
preventing
lapase
reducing hiv
compositions
hiv infection
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA 2303591
Other languages
French (fr)
Other versions
CA2303591C (en
Inventor
Gabriel Pulido-Cejudo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Canbreal Therodiagnostics Canada Holding Corp
Canada Minister of Health
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from CA002267481A external-priority patent/CA2267481A1/en
Application filed by Individual filed Critical Individual
Priority to CA 2303591 priority Critical patent/CA2303591C/en
Publication of CA2303591A1 publication Critical patent/CA2303591A1/en
Application granted granted Critical
Publication of CA2303591C publication Critical patent/CA2303591C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/37—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • G01N33/56988—HIV or HTLV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • General Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Cell Biology (AREA)
  • AIDS & HIV (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

In spite of having achieved an in depth and comprehensive genetic structure of the human immunodeficiency virus (HIV) and of that of its several structural and geographical clusters, a very limited success in the prevention and treatment of AIDS
has been attained. Described herein is a method for preventing or reducing HIV
infectivity by using an antibody specific for estrogen-stimulated leucine aminopeptidase (es-LAPase), or one or more inhibitors of LAPase activity, or a combination thereof.
Also described is a method for preventing or reducing HIV infectivity by using an antibody specific for es-LAPase, one or more inhibitors of es-LAPase activity and an anti-estrogen compound. The novel compositions are also defined.
CA 2303591 1999-03-30 2000-03-30 Method and compositions for preventing or reducing hiv infection Expired - Fee Related CA2303591C (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA 2303591 CA2303591C (en) 1999-03-30 2000-03-30 Method and compositions for preventing or reducing hiv infection

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CA2,267,481 1999-03-30
CA002267481A CA2267481A1 (en) 1999-03-30 1999-03-30 Critical interdependency: from the role of estrogen on breast cancer to the susceptibility of women towards hiv infection
CA 2303591 CA2303591C (en) 1999-03-30 2000-03-30 Method and compositions for preventing or reducing hiv infection

Publications (2)

Publication Number Publication Date
CA2303591A1 true CA2303591A1 (en) 2000-09-11
CA2303591C CA2303591C (en) 2002-12-17

Family

ID=25680865

Family Applications (1)

Application Number Title Priority Date Filing Date
CA 2303591 Expired - Fee Related CA2303591C (en) 1999-03-30 2000-03-30 Method and compositions for preventing or reducing hiv infection

Country Status (1)

Country Link
CA (1) CA2303591C (en)

Also Published As

Publication number Publication date
CA2303591C (en) 2002-12-17

Similar Documents

Publication Publication Date Title
CA2173328A1 (en) HIV Protease Inhibitors
BR0009485A (en) Method and compositions for preventing or reducing HIV infection by using leucine aminopeptidase inhibitors
AU2002310156A1 (en) 1,4-disubstituted benzo-fused cycloalkyl urea compounds
WO2004096818A3 (en) Method and compositions for identifying anti-hiv therapeutic compounds
BG102048A (en) Tetrahydrofuran-containing sulphonamides as aspartylprotease inhibitors
AU5729196A (en) Soluble, active hepatitis c virus protease
WO2001010456A3 (en) Peptides that block viral infectivity and methods of use thereof
DE69518840D1 (en) N-(3-amino-2-hydroxybutyl)sulfonamid-derivate as hiv-protease-inhibitoren
WO2004037784A3 (en) Pyrrolidones with anti-hiv activity
AU5694901A (en) Methods and compositions for inhibition of membrane fusion-associated events, including hiv transmission
WO2003015708A3 (en) Composition and method for treating hiv infection
WO1995014011A3 (en) 5,6-dihydropyrone derivatives as protease inhibitors and antiviral agents
AU2002219881A1 (en) Methods and compositions for the treatment of human immunodeficiency virus infection
AU6087194A (en) Hiv protease inhibitors
AU2003217604A1 (en) Method of treating hiv infection by preventing interaction of cd4 and gp120
AU2002326925A1 (en) Process for preparing protease inhibitor intermediates
EP1550667A4 (en) Tyrosinase activity controlling agents, process for producing the same and external preparations containing the same
CA2303591A1 (en) Method and compositions for preventing or reducing hiv infection
CA2248837A1 (en) Method and composition for enhancing biocidal activity
CA2281133A1 (en) Multiple-agents-binding compound and use thereof
EP0379295A3 (en) Anti-tryptase antibody and composition for treatment of aids using the same
CA2345896A1 (en) A method of modulating ion channel functional activity
ATE294790T1 (en) CHLOROMETHYLATION OF THIOPHENE
AU2002360523A1 (en) Compounds to treat hiv infection and aids
MY127289A (en) Caloporoside derivatives, process for the preparation thereof, and the use thereof

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20130402